George Health Enterprises and its subsidiary George Medicines have raised a combined $35m in funding from investors including Bupa Australia to drive pipeline development and commercialisation.
George Health Enterprises, the UK-based commercial arm of George Institute for Global Health operating an integrated healthcare business, secured £27m ($35m) in funding yesterday from investors including health insurance provider Bupa Australia.
The capital is split into a $22m investment in George Health that was co-led by Bupa Australia and private equity fund Federation Asset Management, and $13m for George Medicines that was supplied by Medical Research Commercialisation Fund (MRCF).
MRCF, backed by the government of Australia and managed by…